alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 61 studies with an author at University of Calgary (CA) · free to read (page 2 of 3) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of these 61 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 16,851 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2015-06-18

Neuropsychiatric symptoms (NPS) are common in dementia and in predementia syndromes such as mild cognitive impairment (MCI). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults

✓ Peer-reviewed alzhub usefulness score 56 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2019-02-02

MBI may be an earlier marker of neurodegenerative disease than MCI, captured at the stage of subjective cognitive decline or before, raising the possibility that MBI represents a novel target for dementia clinical trials or prevention strategies. 3 key findings →

Participants: 9,931 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Using Machine Learning to Predict Dementia from Neuropsychiatric Symptom and Neuroimaging Data

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Journal of Alzheimer's disease : JAD 2020-01-01

Baseline NPS, categorized for MBI domain and duration, have prognostic utility in addition to brain morphology measures for predicting diagnosis change using ML. 2 key findings →

Participants: 102 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Machine-learning-based COVID-19 mortality prediction model and identification of patients at low and high risk of dying

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Critical care (London, England) 2021-09-08

An accurate COVID-19 mortality prediction model among hospitalized patients based on the clinical features and comorbidities may play a beneficial role in the clinical setting to better management of patients with COVID-19. 3 key findings →

Participants: 250 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Toward compassionate communication: a rapid review on facilitating the dementia disclosure process

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer s & Dementia 2025-08-01

Individuals with dementia and their care partners often report dissatisfaction with the disclosure process due to insufficient information and support. 2 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2020-07-29

Since 1989, four Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (CCCDTD) have provided evidence-based dementia guidelines for Canadian clinicians and researchers. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Journal of neurology 2017-01-03

Neurogenic orthostatic hypotension (nOH) is common in patients with neurodegenerative disorders such as Parkinson's disease, multiple system atrophy, pure autonomic failure, dementia with Lewy bodies, and peripheral neuropathies including amyloid or diabetic neuropathy. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Alzheimer's & dementia (New York, N. Y.) 2017-08-05

Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden

✓ Peer-reviewed alzhub usefulness score 53 out of 100. International psychogeriatrics 2017-09-07

Prevalence estimates across MBI domains were affective dysregulation (77.8%); impulse control (64.4%); decreased motivation (51.7%); social inappropriateness (27.8%); and abnormal perception or thought content (8.7%). 2 key findings →

Participants: 119 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Study protocol: pragmatic randomized control trial of my tools 4 care- in care (MT4C-in care) a web-based tool for family Carers of persons with dementia residing in long term care

✓ Peer-reviewed alzhub usefulness score 52 out of 100. BMC geriatrics 2020-08-10

Data collection will begin in four Canadian provinces (Alberta, Manitoba, Ontario and Saskatchewan) in February 2020 and is expected to be completed in June 2021. 3 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Volumetric Changes in Cerebellar Transverse Zones: Age and Sex Effects in Health and Neurological Disorders

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Human Brain Mapping 2025-04-15

Cerebellar volumetric changes are intricately linked to aging, with distinct patterns across its transverse zones, the functional subdivisions characterized by unique cytoarchitectural and connectivity profiles. 5 key findings →

Participants: 45,000 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Peripheral biomarkers associated with apathy and predicting response to methylphenidate: Secondary analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET2) study

✓ Peer-reviewed alzhub usefulness score 51 out of 100. International Psychogeriatrics 2026-01-01

In the ADMET2 biomarker subset (n = 44, MPH:21, age:75 years, MMSE:20.2), higher baseline TNF was associated with higher M6 NPI-A [B(SE)= 6.86 (1.71), p = .0003], and multivariable models found lower baseline TNF [B(SE)= 8.28(1.61), p < .001] and higher baseline S100B [B(SE)= -6.41(1.95), p = .002] were associated with lower M6 NPI-A. Exploratory analyses suggested that higher baseline NfL significantly interacted with treatment to predict lower M6 NPI-A [B(SE)= -8.36(4.21), p = .05], only when adjusting for cognition. 5 key findings →

Participants: 44 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria

✓ Peer-reviewed alzhub usefulness score 50 out of 100. International psychogeriatrics 2017-09-13

Affective symptoms are of prognostic utility, but interventions to prevent dementia syndromes are limited. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives

✓ Peer-reviewed alzhub usefulness score 49 out of 100. The Australian and New Zealand journal of psychiatry 2021-11-17

Treatment-resistant schizophrenia does not appear to be associated with neuronal, particularly axonal degeneration. 4 key findings →

Participants: 82 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Impaired neurovascular coupling in aging and Alzheimer's disease: Contribution of astrocyte dysfunction and endothelial impairment to cognitive decline

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Experimental gerontology 2016-11-12

The importance of (micro)vascular contributions to cognitive impairment and dementia (VCID) in aging cannot be overemphasized, and the pathogenesis and prevention of age-related cerebromicrovascular pathologies are a subject of intensive research. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice

✓ Peer-reviewed alzhub usefulness score 48 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2002-03-01

3-4-(2-Fluoro-alpha-methyl-[1,1'-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester (NCX-2216), a nitric oxide (NO)-releasing derivative of the cyclooxygenase-1-preferring nonsteroidal anti-inflammatory drug (NSAID) flurbiprofen, dramatically reduced both beta-amyloid (Abeta) loads and Congo red staining in doubly transgenic (Tg) amyloid precursor protein plus presenilin-1 mice when administered at 375 ppm in diet between 7 and 12 months of age. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Vascular risk factor associations with subjective cognitive decline and mild behavioural impairment

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Brain Communications 2025-01-01

Having three or more vascular risk factors (odds ratio = 1.23, 95% confidence interval [1.04-1.47]), actively smoking (odds ratio = 1.54, 95% confidence interval [1.29-1.82]), being overweight (odds ratio = 1.46, 95% confidence interval [1.22-1.74]), and having diabetes (odds ratio = 1.29, 95% confidence interval [1.09-1.53]) were associated with higher odds of subjective cognitive decline. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Enhancing Alzheimer Disease Detection Using Neuropsychiatric Symptoms: The Role of Mild Behavioural Impairment in the Revised NIA-AA Research Framework

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of geriatric psychiatry and neurology 2025-08-13

BackgroundAs the prevalence of Alzheimer disease (AD) rises, early identification of at-risk individuals is essential for effective intervention. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events